Probatebeta
Company

Chimerix

As of the edition of 20 October 2026, Chimerix runs 2 drugs, 2 of them marketed; it is on route A at 0 targets and on route B at 2 targets.

Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.

Drugs by status

StatusCount
Marketed2
Total2

Marketed drugs and when their US protection ends

DrugUS protectionRoute B rows
DordaviproneEnds 2032 (exclusivity)2
BrincidofovirEnds 2034 (patent)0

A route B row is one company at one target.

Where it needs a new molecule

Route A at 0 targets, route B at 2 targets.

Three of its 2 rows, by target and route
TargetRoute
CLPP ATP-dependent Clp protease proteolytic subunit, mitochondrialRoute B
DRD2 Dopamine receptor D2Route B

All 2 rows on route A or B

In the product

2 company-target rows on route A or B; 0 are not shown here, and no score is.

See all 2 targets where Chimerix needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.